CN101264347A - Drug coating applied to balloon surface of balloon catheter balloon for relieving vascular restenosis - Google Patents
Drug coating applied to balloon surface of balloon catheter balloon for relieving vascular restenosis Download PDFInfo
- Publication number
- CN101264347A CN101264347A CNA2007101504138A CN200710150413A CN101264347A CN 101264347 A CN101264347 A CN 101264347A CN A2007101504138 A CNA2007101504138 A CN A2007101504138A CN 200710150413 A CN200710150413 A CN 200710150413A CN 101264347 A CN101264347 A CN 101264347A
- Authority
- CN
- China
- Prior art keywords
- coated
- foley
- balloon surface
- tube
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 107
- 229940079593 drug Drugs 0.000 title claims abstract description 48
- 208000037803 restenosis Diseases 0.000 title claims abstract description 25
- 238000000576 coating method Methods 0.000 title claims abstract description 16
- 239000011248 coating agent Substances 0.000 title claims abstract description 13
- 230000002792 vascular Effects 0.000 title claims description 15
- 230000006378 damage Effects 0.000 claims abstract description 28
- 239000003937 drug carrier Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 230000002980 postoperative effect Effects 0.000 claims abstract description 12
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 70
- 239000002904 solvent Substances 0.000 claims description 47
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 24
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 24
- 230000001954 sterilising effect Effects 0.000 claims description 24
- 238000004659 sterilization and disinfection Methods 0.000 claims description 24
- 230000003064 anti-oxidating effect Effects 0.000 claims description 23
- 229920001577 copolymer Polymers 0.000 claims description 23
- 229960003180 glutathione Drugs 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 20
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 20
- 229940088598 enzyme Drugs 0.000 claims description 20
- 235000003969 glutathione Nutrition 0.000 claims description 19
- 102000016938 Catalase Human genes 0.000 claims description 18
- 108010053835 Catalase Proteins 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 16
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 16
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 16
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 16
- 229930003427 Vitamin E Natural products 0.000 claims description 15
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 15
- 235000019165 vitamin E Nutrition 0.000 claims description 15
- 229940046009 vitamin E Drugs 0.000 claims description 15
- 239000011709 vitamin E Substances 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 12
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 11
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 11
- 239000011651 chromium Substances 0.000 claims description 11
- 235000012661 lycopene Nutrition 0.000 claims description 11
- 229960004999 lycopene Drugs 0.000 claims description 11
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 11
- 239000001751 lycopene Substances 0.000 claims description 11
- 239000011572 manganese Substances 0.000 claims description 11
- 239000011669 selenium Substances 0.000 claims description 11
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 102000003992 Peroxidases Human genes 0.000 claims description 10
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 10
- 235000013734 beta-carotene Nutrition 0.000 claims description 10
- 239000011648 beta-carotene Substances 0.000 claims description 10
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 10
- 229960002747 betacarotene Drugs 0.000 claims description 10
- 229910052756 noble gas Inorganic materials 0.000 claims description 10
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 10
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 10
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 9
- 229910052804 chromium Inorganic materials 0.000 claims description 9
- 229910052748 manganese Inorganic materials 0.000 claims description 9
- 229960001592 paclitaxel Drugs 0.000 claims description 9
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 9
- 239000004626 polylactic acid Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 229910052711 selenium Inorganic materials 0.000 claims description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 9
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 8
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 8
- QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 claims description 8
- 229920002635 polyurethane Polymers 0.000 claims description 8
- 239000004814 polyurethane Substances 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 229940105657 catalase Drugs 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 7
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 7
- 229960002930 sirolimus Drugs 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- 108010092160 Dactinomycin Proteins 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 6
- 229960000640 dactinomycin Drugs 0.000 claims description 6
- 239000004633 polyglycolic acid Substances 0.000 claims description 6
- YLWAQARRNQVEHD-PBZHRCKQSA-N tazettine Chemical compound O([C@]1(O)CN2C)CC3=CC=4OCOC=4C=C3[C@]31[C@@H]2C[C@H](OC)C=C3 YLWAQARRNQVEHD-PBZHRCKQSA-N 0.000 claims description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 5
- 239000002464 receptor antagonist Substances 0.000 claims description 5
- 229940044551 receptor antagonist Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 108010074415 Angiogenic Proteins Proteins 0.000 claims description 4
- 102000008076 Angiogenic Proteins Human genes 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 102000007625 Hirudins Human genes 0.000 claims description 4
- 108010007267 Hirudins Proteins 0.000 claims description 4
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims description 4
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims description 4
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 claims description 4
- 229920000388 Polyphosphate Polymers 0.000 claims description 4
- GDVNLLJNADMLLR-BBRMVZONSA-N Spergualin Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)C[C@@H](O)CCCCN=C(N)N GDVNLLJNADMLLR-BBRMVZONSA-N 0.000 claims description 4
- JBVZQDJNGFOSNX-UHFFFAOYSA-N Spergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CC(O)CCCCNC(=CN)N JBVZQDJNGFOSNX-UHFFFAOYSA-N 0.000 claims description 4
- 229930194217 Stevastelin Natural products 0.000 claims description 4
- NKNPHSJWQZXWIX-DCVDGXQQSA-N Tetranactin Chemical compound C[C@H]([C@H]1CC[C@H](O1)C[C@@H](OC(=O)[C@@H](C)[C@@H]1CC[C@@H](O1)C[C@@H](CC)OC(=O)[C@H](C)[C@H]1CC[C@H](O1)C[C@H](CC)OC(=O)[C@H]1C)CC)C(=O)O[C@H](CC)C[C@H]2CC[C@@H]1O2 NKNPHSJWQZXWIX-DCVDGXQQSA-N 0.000 claims description 4
- NKNPHSJWQZXWIX-UHFFFAOYSA-N Tetranactin Natural products CC1C(=O)OC(CC)CC(O2)CCC2C(C)C(=O)OC(CC)CC(O2)CCC2C(C)C(=O)OC(CC)CC(O2)CCC2C(C)C(=O)OC(CC)CC2CCC1O2 NKNPHSJWQZXWIX-UHFFFAOYSA-N 0.000 claims description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 230000000702 anti-platelet effect Effects 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 claims description 4
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 4
- 229960003009 clopidogrel Drugs 0.000 claims description 4
- 108010017278 depsidomycin Proteins 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 229940006607 hirudin Drugs 0.000 claims description 4
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 4
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 claims description 4
- 239000001205 polyphosphate Substances 0.000 claims description 4
- 235000011176 polyphosphates Nutrition 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- XEEPVFFWNATEGX-IUHNQTRMSA-N Tazettadiol Natural products C1=C(CO)C([C@]23[C@H](O)CN(C)[C@H]2C[C@@H](C=C3)OC)=CC2=C1OCO2 XEEPVFFWNATEGX-IUHNQTRMSA-N 0.000 claims description 3
- 238000007334 copolymerization reaction Methods 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229940075065 polyvinyl acetate Drugs 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- KLJOYDMUWKSYBP-SLEMLFNQSA-N pretazettine Natural products CO[C@H]1C[C@@H]2N(C)C[C@@H]3O[C@@H](O)c4cc5OCOc5cc4[C@]23C=C1 KLJOYDMUWKSYBP-SLEMLFNQSA-N 0.000 claims description 3
- YLWAQARRNQVEHD-UHFFFAOYSA-N sekisanoline Natural products CN1CC2(O)OCC3=CC=4OCOC=4C=C3C32C1CC(OC)C=C3 YLWAQARRNQVEHD-UHFFFAOYSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 229910052729 chemical element Inorganic materials 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 abstract description 21
- 230000003078 antioxidant effect Effects 0.000 abstract description 16
- 239000003963 antioxidant agent Substances 0.000 abstract description 13
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 9
- 230000000747 cardiac effect Effects 0.000 abstract description 4
- 230000004064 dysfunction Effects 0.000 abstract description 4
- 230000002137 anti-vascular effect Effects 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 238000005507 spraying Methods 0.000 description 23
- 238000001035 drying Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- 239000007921 spray Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 9
- 208000029078 coronary artery disease Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- -1 nitric oxide free radical Chemical class 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000003618 dip coating Methods 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000000941 radioactive substance Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- 239000008016 pharmaceutical coating Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 210000003291 sinus of valsalva Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention relates to the field of medical instruments, in particular to a drug coating which can relieve postoperative restenosis of blood vessels and reduce free radical damage and is coated on the surface of a balloon in a balloon catheter. The drug coating is composed of 1% -99% of drugs and 1% -99% of drug carriers, and the drugs can be selected from single antioxidant drugs, mixture of multiple antioxidant drugs, and mixture of single or multiple antioxidant drugs and anti-vascular restenosis drugs. And the medicine is uniformly coated on the surface of the air bag by adopting a mixing or layered coating method, and the damage of free radicals to human cells and tissues after myocardial ischemia reperfusion can be effectively relieved and reduced by local administration, so that the treatment of the cardiac dysfunction is finally realized.
Description
Technical field
The present invention relates to medical instruments field, particularly a kind ofly adopt the alleviating vascular restenosis that anti-oxidation medicine coats and be coated in the medication coat of foley's tube balloon surface.
Background technology
Atherosclerosis is the important diseases that influences health, and the pathological changes that wherein feeds through to heart coronary artery is called coronary heart disease.Coronary heart disease often causes deficiency myocardial blood supply, and gently then angina pectoris is heavy then cause myocardial infarction, even dead.The U.S. in 2000 ischemic heart desease death accounts for 21.4% of dead sum, and wherein acute myocardial infarction death accounts for 8%.
It is clinical medical in recent years impressive progress that patients of acute myocardial infarction adopts the treatment of revascularization art, because dredging vascellum or reproduce blood vessel and make cardiac muscular tissue obtain the perfusion again of blood behind the ischemia really can be received excellent curative as a rule.Yet, recover again sometimes to increase the weight of myocardial structural damages and dysfunction on the contrary behind the blood flow, even cause severe arrhythmia.The damage that how can reduce ischemia-reperfusion effectively is the problem that domestic and international medical circle is paid close attention to always.
In recent years, along with the coronary artery balloon expandable forms applying of art, with the intravascular stent that contains radioactive substance is that patients with coronary heart disease brings glad tidings, but, preparation and use to carry out protection to lonizing radiation because containing the radioactive substance intravascular stent, it is very complicated that operation is implemented, simultaneously because therefore the problem that also exists the Excreta that must prevent to contain radioactive substance that environment is polluted makes it be restricted in clinical use.
Produced afterwards into preventing vascular restenosis drug-carried coat support, this type of medicine is at platelet GBIIb/IIIa receptor antagonist or influences cell division, quicken the cancer therapy drug of natural death of cerebral cells, but there is in controlled-release coating processing technology instability or the operation process damage to the rack surface controlled release layer, and be created in the too fast too high possibility of local blood drug level that causes of rate of release in the human body, bring the further risk of damage of myocardial cell.
Method by intravenous injection antioxidant (coenzyme Q10) also once was applied to clinical, because the time is short, can not keep local drug concentration, and curative effect is also undesirable.Therefore how local application and use which kind of ingredient collocation to become the another development trend of research medicine slow release stent with the cooperative effect that reaches treatment and protection.
The theoretical basis that the present invention is based on is carried out following analysis:
The basic theories of 1 free radical
Free radical is the group that has one or more unpaired electronics in out orbit, and this is the material that a class has greater activity.Free radical is the interior intermediate product [list of references 1] about catalytic aerobic metabolism process of enzyme system and electron transport chain electron transport of organism, also is the intermediate product that bio-tissue or cell form in some chemical damage process.It brings into play the effect of strong oxidizer in vivo directly or indirectly, thereby damage organism macromole and various kinds of cell composition, also can react with other materials (as nucleic acid, protein, lipid etc.), generate the oxide or the peroxide of this class material, to body cause damage [list of references 2].Free radical comprises ultra-oxygen anion free radical (O
2 -), hydroxy radical (OH), hydrogen peroxide (H
2O
2), singlet oxygen (O
2 -), hydroperoxyl radical (HOO), peroxy radical (ROO), nitric oxide free radical (NO), semiquinone free radical (QH), peroxynitrite base (ONOO
-); Alkane free radical (R), alkoxy free group (RO), alkane peroxy radical (ROO); Fat oxygen-derived free radicals (LO), fat peroxy radical (LOO) isoreactivity oxygen (ROS).With the intermediate product malonaldehyde (malondialdehyde MDA) of lipid peroxidation representative product [list of references 3] as lipid peroxidation, it is used as the sensitive indicator of weighing the body Radical Metabolism, and its content can reflect objectively that body produces the level of free radical.
2 lipid peroxidations
It is that the main diseases of coronary atherosclerosis is because of [list of references 4] that serum oxidized low-density lipoprotein (OxLDL) raises.Diagnosis and treatment for coronary atherosclerosis, intervention property heart radiology is by means of the development of image apparatus and conduit technology, conduit can be positioned over aortic sinus and near-end coronarius through femoral artery, use balloon tamponade, the atherosis narrow blood vessel of expansion or placement stainless steel stent and strut blood vessel, to improve the blood supply of heart muscle tissue.This technology and surgery's coronary bypass has formed the method that complements one another.The several years patient vessel is narrow once more behind the transluminal coronary angioplasty still has higher probability, warn people when the expansion of seeking narrow blood vessel, should strengthen monitoring, and more need strengthen control [list of references 5] the OxLDL level in the blood circulation to coronary restenosis.
The control of coronary heart disease is atherosclerosis to a great extent, and its key link is to reduce OxLDL, thereby avoids macrophage phagocytic, forms foam cell, and the triggering speckle forms, fibrosis causes tremulous pulse medicated porridge sample to change [list of references 6].So removing OxLDL in blood becomes prevention and treats arteriosclerotic key, also becomes an important ring of coronary heart disease control simultaneously.
OxLDL is intravital free radical source, and macrophage is not attacked natural low density lipoprotein, LDL (LDL), thereby does not cause arteriosclerotic lesion.Therefore antioxidant becomes the target that the research of resisting coronary heart disease pharmaceutics is paid close attention to.Water miscible antioxidant is by preventing lipophilic vitamin E loss, and the LDL in the protection blood avoids oxidation [list of references 2]; The LDL of blood vessel endothelium lower floor then relies on remaining fat antioxidant action.These chemical compounds will be the important sources that exploitation prevents and treats arteriosclerosis and medicaments for coronary disease.
The intravital antioxidant system of 3 machines
Enzyme antioxidant superoxide dismutase (SOD) is to eliminate body O
2 -Main enzyme, be distributed in the endochylema and mitochondrion of cell, there are two kinds of isozyme Cu in it, Zn-SOD (endochylema) and Mn-SOD (mitochondrion), its activity high definition is more removed the ability strong more [list of references 7] of free radical.Catalase (CAT) is to eliminate hydrogen peroxide (H in the body
2O
2) important enzyme, be present in microgranule and the mitochondrion.Reduced glutathion (GSH) can be protected the activity of sulfydryl enzyme as the intravital important protection factor, and it can also make superoxide anion (O under the catalysis of GSH-PX
2 -), hydrogen peroxide (H
2O
2) and fat hydroperoxides (LOOH) become the hypotoxicity material, protection biomembrane and biomacromolecule are avoided radical damage play an important role.The important enzyme that a kind of catalyzing hydrogen peroxide that extensively exists in the glutathion peroxidase (GSH-PX), body decomposes, catalysis GSH plays the effect of protection membrane structure and functional completeness to the reduction reaction of hydrogen peroxide specifically.Glutathione transferase (CST) extensively is present in mammiferous each tissue, content is particularly abundant in the hepatocyte, participate in the important function of detoxification of liver, and can combine with the electrophilic group of chemical substance by catalysis GSH, finally form mercapturic acid and excrete [list of references 8].
The non-enzyme antioxidant is with its cancellation free radical, prevention or interrupt lipid peroxidation, stabilate film and bring into play the antioxidative effect.Mainly comprise: liposoluble substance, as lycopene, vitamin E, beta-carotene, coenzyme Q10 and flavone compound etc.; Water-soluble substances is as vitamin C, CSH etc.In addition, trace element (zinc (Zn), selenium (Se), chromium (Cr), manganese (Mn)) participates in the biosynthesis of enzyme antioxidant, and plays antioxidative effect [list of references 9] with the character of self electron transport.
The present invention is by above-mentioned rationale and cause damage problem to carry out sufficient research and analysis to easy pair cell of myocardial ischemia-reperfusion and tissue, show after deliberation, myocardial ischemia reperfusion injury can further strengthen myocardial infarction area, the cardiac dysfunction degree is heavier than acute myocardial infarction, and case fatality rate is higher.During reperfusion injury, because free radical effect and Ca
2 +Overload has damaged cell membrane and mitochondrion, and permeability of cell membrane is increased, and tissue necrosis causes the various enzymes of myocardial cell to leak outside, and is released into blood, causes that a series of serum zymetologys change [list of references 10].Serum creatine kinase isozyme (CK-MB), the determination of activity of lactate dehydrogenase L DH and glutamic oxaloacetic transaminase, GOT AST can be used as observe myocardial ischemia reperfusion injury degree and medicine resist myocardial ischemia the reperfusion injury curative effect and more after one of index.
During myocardial ischemia reperfusion injury, arterial endothelium is impaired, the prostacyclin (PGI) that mainly results from the coronary blood endothelial cell is synthesized disturbed, subcutaneous collagen tissue in platelet is killed and invested further discharges the vaso-excitor material based on thromboxane A (TXA).TXA can be used as carrier and directly promotes Ca
2 +Interior stream and dense tubular system Ca
2 +Put, thereby promote platelet aggregation and local vasoconstriction, increase the weight of endothelial injury [list of references 10].
Therefore oxygen-derived free radicals is one of key factor that causes reperfusion injury to histiocytic infringement.In myocardial ischemia and the refilling process; the superoxide dismutase (SOD) of cardiac muscle; the content of catalase (CAT) and glutathion peroxidase (GSH-Px) etc. reduces; malonaldehyde (MDA) content increases, so exogenous antioxidant or the free radical scavenger of giving is to ischemia and pour into cardiac muscle again and have significant protective effect [list of references 11].And, improve the endogenous activities of antioxidant enzymes and further alleviate oxygen-derived free radicals induced myocardial injury by suppressing the lipid peroxidation process.
Summary of the invention
In sum; anti-oxidation medicine should become treatment and protect the main medicine that human body cell and tissue is caused damage because of ischemia-reperfusion; it is a carrier with enzyme and non-enzyme antioxidant with the Biodegradable polymer; be coated in the foley's tube on the balloon surface; and the analysis by pharmacological action; it can singly be planted and prepare; again can multiple mixed preparing; can also with anti-angiogenic restenosis medicaments mixed preparing; by local application, can alleviate effectively and reduce because of the final realization treatment of the damage of radical pair human body cell and tissue behind myocardial ischemia-reperfusion cardiac dysfunction.
Provided by the inventionly alleviate postoperative vascular restenosis and radical damage and be coated in the medication coat of balloon surface in the foley's tube, the balloon surface medication coat by the anti-oxidation medicine of 1%-99% or 1%-99% anti-oxidation medicine and anti-angiogenic restenosis medicaments mix and the pharmaceutical carrier of 1%-99% is formed.
Anti-oxidation medicine of the present invention comprises superoxide dismutase (SOD), catalase (CAT), coenzyme Q10, glutathion peroxidase (GSH-PX), lycopene, reduced glutathion (GSH), vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and trace element (zinc (Zn), selenium (Se), chromium (Cr), product behind manganese (Mn) and the process molecular modification thereof, in the said medicine any one or any several drugs all can be prepared with pharmaceutical carrier, wherein, any one content of medicines during several drugs mixes should account for the 1%-99% of the total proportion of medicine;
Described anti-angiogenic restenosis class medicine is anticoagulation class medicine, anticancer class medicine, inhibition vascular smooth muscle cell curing class activity inhibitor, anti-inflammatory drug and immunosuppressant, wherein:
Anticoagulation class medicine comprises aspirin, heparin, hirudin, antiplatelet GPIIb/IIIa receptor antagonist, clopidogrel;
Anticancer class medicine comprises colchicine, paclitaxel;
Suppress vascular smooth muscle cell curing class activity inhibitor and comprise angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist;
Anti-inflammatory drug comprises dactinomycin, depsidomycin, KanglemycinC, spergualin, cammunomicin, demethomycin, tetranactin, stevastelins, myriocin, gllooxin;
Immunosuppressant comprises rapamycin, the plain A of ring spore enzyme, the plain C of ring spore enzyme, brefeldin A;
Medication coat of the present invention can be made up of the pharmaceutical carrier of any one and 1%-99% in anti-oxidation medicine superoxide dismutase, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and the zinc of 1%-99%, selenium, chromium, the manganese microelement.
Medication coat of the present invention can be made up of mixing several arbitrarily in anti-oxidation medicine superoxide dismutase, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and the zinc of 1%-99%, selenium, chromium, the manganese microelement and the pharmaceutical carrier of 1%-99%; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
Medication coat of the present invention can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, in the manganese microelement any one and aspirin, heparin, hirudin, antiplatelet GPIIb/IIIa receptor antagonist, clopidogrel, tazettine, paclitaxel, angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist, the plain A of ring spore enzyme, dactinomycin, rapamycin, the plain C of ring spore enzyme, brefeldin A, depsidomycin, KanglemycinC, spergualin, cammunomicin, demethomycin, tetranactin, stevastelins, myriocin, the mixing of any one among the gllooxin and the pharmaceutical carrier of 1%-99% are formed; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
Pharmaceutical carrier of the present invention is Biodegradable material and non-degradable material.Biodegradable material comprises copolymer or the blend between PTMC and PLA, Polyethylene Glycol, polyvinylpyrrolidone (PVP), glutin, polyurethane, poly phosphate or the polyglycolic acid ester, its copolymerization or blend ratio are 1%: 99%-99%: in 1% (concentration ratio) scope, and its molecular weight 5000-500000 dalton.
The non-degradable material comprises copolymer or the blend between plastic of poly vinyl acetate and polymethyl methacrylate, sodium alginate, gelatin, arabic gum or the polybutyl methacrylate, its copolymerization or blend ratio are 1%: 99%-99%: in 1% (concentration ratio) scope, and its molecular weight 5000-500000 dalton.
Preparation method provided by the invention comprises two kinds (mainly being the preparations at multicomponent pharmaceutical), and a kind of is with the medicament mixed coating, and another kind is the layering coating.Layering coating should be with anti-angiogenic restenosis class medicine as the intermediate layer, and anti-oxidation medicine is coated in the top layer of air bag.Coating method can adopt the spraying process or the infusion process arbitrary form of medicine coating method, no matter take any method, all should reach coating evenly and its medication coat thickness should be between the 0.1-50 micron, the drug loading of every pair of air bag is between the 10-1000 microgram.
What the preparation method of the embodiment of the invention adopted is spraying process and infusion process, rotatable air bag angle repeats spraying several times in spraying process, it is reached evenly, and the medication coat content on the air bag can be controlled by the concentration of drug solution and the number of times of coating.Its preparation method is as follows:
1. mix coating: pharmaceutical carrier is dissolved in the solvent, adds medicine and stir, after treating fully to dissolve and filtering, evenly be coated in the foley's tube on the balloon surface, and in noble gas solvent flashing, afterwards in vacuum condition dry 12 hours down, ethane via epoxyethane sterilization again.
2. layering coating: pharmaceutical carrier is dissolved in the solvent, adds anti-angiogenic restenosis class medicine and stir, after treating fully dissolving and filtering, evenly be coated in the foley's tube on the balloon surface, and in noble gas solvent flashing; Pharmaceutical carrier is dissolved in the solvent, adds the polyphenoils medicine then and stir, after treating fully to dissolve and filtering, evenly be coated in once more in the foley's tube on the balloon surface, and in noble gas solvent flashing, afterwards in vacuum condition dry 12 hours down, ethane via epoxyethane sterilization again.
The advantage of layering coating is, both can discharge the anti-oxidation medicine skin earlier to reach the purpose of alleviating and reducing because of the damage of radical pair human body cell and tissue behind the myocardial ischemia-reperfusion, the anti-angiogenic restenosis class medicine transition in operation process that can control the intermediate layer is again run off, and just discharges fully and reach lesions position always.
The solvent that compounding pharmaceutical coating solution of the present invention uses is heterocyclic arene class, pure ketone, esters, alkanes, aromatic hydrocarbons and water; Comprise any one of methanol, ethanol, sodium lactate, acetonitrile, isopropyl alcohol, oxolane, acetone, ethyl acetate, dichloromethane, chloroform or purified water.The noble gas that uses in the medication coat preparation process can be any one of other noble gas in nitrogen, helium and the periodic table of chemical element.
The release cycle of anti-oxidation medicine of the present invention is 1 second to 1 hour.
The specific embodiment
Embodiment one: after the 0.3g Polyethylene Glycol is dissolved in 10ml acetone, adding 0.2g superoxide dismutase (SOD) stirs, after dissolving all even filtration, be sprayed on balloon surface in the foley's tube that is covered with the middle medication coat of 0.1g paclitaxel, solvent flashing in nitrogen, and the anglec of rotation repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment two: after the copolymer of 0.2g PTMC and polyurethane (5/95 (mol/mol)) is dissolved in the 10ml acetonitrile, add 0.5g lycopene, 0.01g coenzyme Q10 and 0.01g vitamin E, stir, after dissolving all even filtration, balloon surface in the foley's tube of dip-coating medication coat in the middle of being covered with the 0.1g dactinomycin, solvent flashing in nitrogen, and the anglec of rotation repeats dip-coating several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment three: 0.3g is excellent to be after apparent 370 contrast agent are dissolved in the 10ml ethyl acetate, adding 0.3g coenzyme Q10 and 0.01g rapamycin stirs, after dissolving all even filtration, be expelled to balloon surface in the foley's tube, and the anglec of rotation repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment four: after the copolymer of 0.5g PTMC and polylactic acid (25/75 (mol/mol)) is dissolved in the 10ml acetonitrile, adding 0.1g coenzyme Q10 and 0.2g paclitaxel stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and the anglec of rotation repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment five: after the copolymer of 0.2g PTMC and polyurethane (30/70 (mol/mol)) is dissolved in 10ml ethanol, add the 0.1g coenzyme Q10, stir, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment six: after the 0.4g plastic of poly vinyl acetate is dissolved in 10ml acetone, adding 0.3g coenzyme Q10 and 0.1g ciclosporin A stirs, after dissolving all even filtration, be sprayed on balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment seven: after the copolymer of 0.3g PTMC and polyglycolic acid ester (10/90 (mol/mol)) is dissolved in the 10ml oxolane, add 0.2g superoxide dismutase (SOD) and 0.1g vitamin E, stir, after dissolving all even filtration, be sprayed in the middle of the copolymer (10/90 (mol/mol)) that is covered with 0.1g ciclosporin A and 0.3g PTMC and polylactic acid balloon surface in the foley's tube of medication coat, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment eight: after the copolymer of 0.1g PTMC and polylactic acid (5/95 (mol/mol)) is dissolved in 10ml acetone, adding the 0.2g lycopene stirs, after dissolving all even filtration, be sprayed in the middle of the copolymer (10/90 (mol/mol)) that is covered with 0.1g dactinomycin and 0.3g PTMC and polylactic acid balloon surface in the foley's tube of medication coat, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment nine: after the copolymer of 0.3g PTMC and polylactic acid (10/90 (mol/mol)) is dissolved in the 10ml oxolane, add 0.2g superoxide dismutase (SOD) and 0.1g vitamin E, stir, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment ten: after the copolymer of 0.5g PTMC and polyglycolic acid ester (25/75 (mol/mol)) is dissolved in 10ml ethanol, adding 0.1g beta-carotene and 0.2g paclitaxel stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 11: after the copolymer of 0.3g PTMC and polyurethane (10/90 (mol/mol)) is dissolved in the 10ml isopropyl alcohol, adding the 0.2g vitamin C stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 12: after the copolymer of 0.2g PTMC and poly phosphate (5/95 (mol/mol)) is dissolved in 10ml ethanol, add 0.01g vitamin C, 0.01g coenzyme Q10 and 0.3g vitamin E, stir, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 13: after the copolymer of 0.5g PTMC and polylactic acid (15/85 (mol/mol)) is dissolved in the 10ml acetonitrile, adding 0.02g vitamin C and 0.03g rapamycin stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 14: after the copolymer of 0.3g PTMC and polyglycolic acid ester (25/75 (mol/mol)) is dissolved in the 10ml isopropyl alcohol, adding 0.1g vitamin C and 0.2g paclitaxel stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 15: after the copolymer of 0.4g PTMC and polyurethane (30/70 (mol/mol)) is dissolved in 10ml acetone, adding the plain A of 0.01g vitamin C and 0.01g ring spore enzyme stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 16: after the copolymer of 0.3g PTMC and polyurethane (10/90 (mol/mol)) is dissolved in the 10ml acetonitrile, adding the 0.2g catalase stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 17: after the copolymer of 0.2g PTMC and poly phosphate (5/95 (mol/mol)) is dissolved in 10ml acetone, add 0.1g catalase and 0.1g vitamin E, stir, after dissolving all even filtration, dip-coating balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 18: after the copolymer of 0.5g PTMC and polylactic acid (15/85 (mol/mol)) is dissolved in the 10ml acetonitrile, adding 0.1g catalase and 0.2g rapamycin stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 19: after the copolymer of 0.3g PTMC and polyglycolic acid ester (25/75 (mol/mol)) is dissolved in the 10ml oxolane, adding 0.1g catalase and 0.2g paclitaxel stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, and rotation air bag angle repeats spraying several times, make it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Embodiment 20: after the copolymer of 0.4g PTMC and polyurethane (30/70 (mol/mol)) is dissolved in the 10ml acetonitrile, adding the plain A of 0.01g catalase and 0.1g ring spore enzyme stirs, after dissolving all even filtration, spray to balloon surface in the foley's tube, solvent flashing in nitrogen, and rotation air bag angle repeats spraying several times, makes it evenly be coated on balloon surface, in nitrogen behind the solvent flashing again under vacuum condition in drying at room temperature 12 hours. the ethane via epoxyethane sterilization.
Obviously, the above embodiment of the present invention only is for example clearly is described, and is not to be qualification to embodiment of the present invention.Can also make other changes in different forms on the basis of the above description.Here need not also can't give exhaustive to all embodiments.And these belong to conspicuous variation or the change that spirit of the present invention amplified out and still belong among protection scope of the present invention.
List of references:
[1]Basaga,HS.
Biochemical?aspects?of?free?radicals
Biochem?Cell?Biol,68:989-998,1990.
[2]Sohal,R.S.and?Weindruch,R.
Oxidative?stress,caloric?restriction,and?aging.
Science?273:59-63,1996.
[3]Kumar,S.&?Menon,VP.
Changes?in?levels?of?lipid?peroxides?and?activity?of?superoxide?dusmutase?and?catalase?in?diabetesassociated?with?myocardial?infarction
Ind?J?Exp?Biol,30:122-127,1992.
[4]Stryer,L.
Biochem
Spektrum,Akad.Verlag,4.Auflag,1996.
[5]Springer
The?lancet?drug?profiles:Ginkgo?bilobaBeilage?in?der?Internist,34(5),1-11,1992.
[6]Szibor,M.&?Holtz,J.
Mitochondrial?ageing.
In:Basic?Research?in?Cardiology,Vol.98,No.4,210-218,2003.
[7]Voet,D.&?Voet,JG.
Biochem
VCH,Weinheim,N.Y.,Basel,Cambridge,Tokyo,1.korr.Auflage,504-560,1994.
[8]Takeda,N.
Cardiomyopathies?and?mitochondrial?DNA?mutations
Molecular?and?Cellular?Biochemistry,176:287-290,1997.
[9]Yan,SD.&?Schmidt,AM.&?Anderso,GM.&?Zhang,J.&?Brett,J.et?al.
Enhanced?cellular?oxidant?stress?by?the?interaction?of?advanced?glycation?endothelial?products?withtheir?receptors/binding?proteins
The?Journal?of?Biological?Chemistry,13:9889-9897,1994.
[10]Takeymann,N.&?Matsuo,N.&?Tanaka,T.
Oxidative?damage?to?mitochondria?by?the?Ca++-dependent?inner?membrane?permeability?transitionBiochem.J,294:719-725,1993.
[11]Xiaoyan?Men
Study?no?the?Injury?Caused?by?the?Oxygen-derived?Free?Radicals?at?Heart?Failure?of?CHDHeilongjlang?medical?journa
1004-5775(2005)06-0410-02
Claims (10)
1. can alleviate the postoperative vascular restenosis is coated in balloon surface in the foley's tube with reducing radical damage medication coat for one kind, it is characterized in that, the blood vessel stent drug coating by the anti-oxidation medicine of 1%-99% or 1%-99% anti-oxidation medicine and anti-angiogenic restenosis medicaments mix and the pharmaceutical carrier of 1%-99% is formed.
2. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, it is characterized in that described medication coat can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, the pharmaceutical carrier of in the manganese microelement any one and 1%-99% is formed.
3. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, it is characterized in that described medication coat can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, arbitrarily several mixing and the pharmaceutical carrier of 1%-99% are formed in the manganese microelement; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
4. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, it is characterized in that described medication coat can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, in the manganese microelement any one and aspirin, heparin, hirudin, antiplatelet GPIIb/IIIa receptor antagonist, clopidogrel, tazettine, paclitaxel, angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist, the plain A of ring spore enzyme, dactinomycin, rapamycin, the plain C of ring spore enzyme, brefeldin A, depsidomycin, KanglemycinC, spergualin, cammunomicin, demethomycin, tetranactin, stevastelins, myriocin, the mixing of any one among the gllooxin and the pharmaceutical carrier of 1%-99% are formed; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
5. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, described medication coat can be by the anti-oxidation medicine superoxide dismutase of 1%-99%, catalase, coenzyme Q10, glutathion peroxidase, lycopene, reduced glutathion, vitamin E, beta-carotene, vitamin C, Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT) and zinc, selenium, chromium, any several and aspirin in the manganese microelement, heparin, hirudin, antiplatelet GPIIb/IIIa receptor antagonist, clopidogrel, tazettine, paclitaxel, angiogenic peptide, 17-hydroxy-11-dehydrocorticosterone, calcium ion antagonist, the plain A of ring spore enzyme, dactinomycin, rapamycin, the plain C of ring spore enzyme, brefeldin A, depsidomycin, KanglemycinC, spergualin, cammunomicin, demethomycin, tetranactin, stevastelins, myriocin, the mixing of any one among the gllooxin and the pharmaceutical carrier of 1%-99% are formed; Wherein, the content of any one anti-oxidation medicine in the medicament mixed should account for the 1%-99% of the total proportion of medicine.
6. describedly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube as claim 1,2,3,4,5, it is characterized in that described pharmaceutical carrier can be copolymer or in the blend any one between PTMC and PLA, Polyethylene Glycol, polyvinylpyrrolidone (PVP), glutin, polyurethane, poly phosphate or the polyglycolic acid ester; Perhaps can be copolymer or in the blend any one between plastic of poly vinyl acetate and polymethyl methacrylate, sodium alginate, gelatin, arabic gum or the polybutyl methacrylate, its copolymerization or blend ratio be all 1%: 99%-99%: in 1% scope.
7. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, its preparation method is as follows: pharmaceutical carrier is dissolved in the solvent, adding medicine stirs, after treating fully dissolving and filtration, evenly be coated in the foley's tube on the balloon surface, and in noble gas solvent flashing, afterwards in vacuum condition dry 12 hours down, ethane via epoxyethane sterilization again.
8. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, another kind of preparation method is as follows: pharmaceutical carrier is dissolved in the solvent, adding anti-angiogenic restenosis class medicine stirs, after treating fully dissolving and filtration, evenly be coated in the foley's tube on the balloon surface, and in noble gas solvent flashing; Pharmaceutical carrier is dissolved in the solvent, adds the polyphenoils medicine then and stir, after treating fully to dissolve and filtering, evenly be coated in once more in the foley's tube on the balloon surface, and in noble gas solvent flashing, afterwards in vacuum condition dry 12 hours down, ethane via epoxyethane sterilization again.
9. describedly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the preparation method of the medication coat of balloon surface in the foley's tube as claim 7 or 8, it is characterized in that described solvent adopts any one in methanol, ethanol, sodium lactate, acetonitrile, isopropyl alcohol, oxolane, acetone, ethyl acetate, dichloromethane, chloroform or the purified water; Described noble gas can use any one of other noble gas in nitrogen, helium or the periodic table of chemical element.
10. as claimed in claim 1ly alleviate the postoperative vascular restenosis and reduce radical damage and be coated in the medication coat of balloon surface in the foley's tube, it is characterized in that, described medication coat thickness is between the 0.1-50 micron, and the drug loading of every pair of air bag is between the 10-1000 microgram; The release cycle of described anti-oxidation medicine is 1 second to 1 hour.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101504138A CN101264347A (en) | 2007-11-27 | 2007-11-27 | Drug coating applied to balloon surface of balloon catheter balloon for relieving vascular restenosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101504138A CN101264347A (en) | 2007-11-27 | 2007-11-27 | Drug coating applied to balloon surface of balloon catheter balloon for relieving vascular restenosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101264347A true CN101264347A (en) | 2008-09-17 |
Family
ID=39987181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101504138A Pending CN101264347A (en) | 2007-11-27 | 2007-11-27 | Drug coating applied to balloon surface of balloon catheter balloon for relieving vascular restenosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101264347A (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
CN102791302A (en) * | 2009-12-11 | 2012-11-21 | 雅培心血管系统有限公司 | Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon |
CN102883753A (en) * | 2010-03-25 | 2013-01-16 | 路通医疗股份有限公司 | Drug releasing coatings for medical devices |
CN103301513A (en) * | 2013-06-09 | 2013-09-18 | 诸辉 | Preparation method of intravascular stent with pharmaceutical enzyme coating |
JP2014518724A (en) * | 2011-05-25 | 2014-08-07 | コーディス・コーポレイション | Expandable device coated with rapamycin composition |
JP2014523267A (en) * | 2011-05-25 | 2014-09-11 | コーディス・コーポレイション | Expandable device coated with paclitaxel composition |
CN104511084A (en) * | 2014-12-30 | 2015-04-15 | 深圳市信立泰生物医疗工程有限公司 | Balloon catheter |
CN104857573A (en) * | 2010-03-25 | 2015-08-26 | 路通医疗股份有限公司 | Drug releasing coating for medical device |
CN105105892A (en) * | 2015-08-04 | 2015-12-02 | 王显 | Medicine elution balloon |
JP2016510608A (en) * | 2013-03-07 | 2016-04-11 | アボット カーディオバスキュラー システムズ インコーポレイテッド | Implantable medical device comprising a macrocyclic triene lactone drug and a minimum amount of an antioxidant stabilizer and method of manufacture |
US9694111B2 (en) | 2006-11-20 | 2017-07-04 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9737691B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9751081B2 (en) | 2014-12-01 | 2017-09-05 | Clemson University | Self-regenerating antioxidant catalysts and methods of using the same |
US9757351B2 (en) | 2006-11-20 | 2017-09-12 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids |
US9764065B2 (en) | 2006-11-20 | 2017-09-19 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9937159B2 (en) | 2006-11-20 | 2018-04-10 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
CN110935070A (en) * | 2012-10-18 | 2020-03-31 | 米歇尔技术公司 | Drug delivery medical device |
CN111407930A (en) * | 2020-03-19 | 2020-07-14 | 中国科学院长春应用化学研究所 | Polymer bionic coating and preparation method thereof |
CN111803718A (en) * | 2020-07-02 | 2020-10-23 | 西安交通大学医学院第二附属医院 | Anti-fibrosis drug sustained-release coating and preparation method thereof |
CN112642045A (en) * | 2021-01-08 | 2021-04-13 | 北京先瑞达医疗科技有限公司 | Drug coating conveying device and preparation method thereof |
-
2007
- 2007-11-27 CN CNA2007101504138A patent/CN101264347A/en active Pending
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9764065B2 (en) | 2006-11-20 | 2017-09-19 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9937159B2 (en) | 2006-11-20 | 2018-04-10 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9737691B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US10912931B2 (en) | 2006-11-20 | 2021-02-09 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US10994055B2 (en) | 2006-11-20 | 2021-05-04 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US10485958B2 (en) | 2006-11-20 | 2019-11-26 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US10485959B2 (en) | 2006-11-20 | 2019-11-26 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US11534430B2 (en) | 2006-11-20 | 2022-12-27 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9694111B2 (en) | 2006-11-20 | 2017-07-04 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US11376404B2 (en) | 2006-11-20 | 2022-07-05 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US10835719B2 (en) | 2006-11-20 | 2020-11-17 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US10881644B2 (en) | 2006-11-20 | 2021-01-05 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9757544B2 (en) | 2006-11-20 | 2017-09-12 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9757351B2 (en) | 2006-11-20 | 2017-09-12 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
CN102791302A (en) * | 2009-12-11 | 2012-11-21 | 雅培心血管系统有限公司 | Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon |
CN102791302B (en) * | 2009-12-11 | 2017-03-01 | 雅培心血管系统有限公司 | Hydrophobic therapeutic agent for the sacculus of coated with drug and solid emulsifier coating |
CN102883753B (en) * | 2010-03-25 | 2015-04-15 | 路通医疗股份有限公司 | Drug releasing coatings for medical devices |
CN104857573A (en) * | 2010-03-25 | 2015-08-26 | 路通医疗股份有限公司 | Drug releasing coating for medical device |
CN102883753A (en) * | 2010-03-25 | 2013-01-16 | 路通医疗股份有限公司 | Drug releasing coatings for medical devices |
JP2014523267A (en) * | 2011-05-25 | 2014-09-11 | コーディス・コーポレイション | Expandable device coated with paclitaxel composition |
JP2014518724A (en) * | 2011-05-25 | 2014-08-07 | コーディス・コーポレイション | Expandable device coated with rapamycin composition |
CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
WO2013097717A1 (en) * | 2011-12-27 | 2013-07-04 | 上海微创医疗器械(集团)有限公司 | Drug-eluting balloon tube |
CN110935070A (en) * | 2012-10-18 | 2020-03-31 | 米歇尔技术公司 | Drug delivery medical device |
JP2016510608A (en) * | 2013-03-07 | 2016-04-11 | アボット カーディオバスキュラー システムズ インコーポレイテッド | Implantable medical device comprising a macrocyclic triene lactone drug and a minimum amount of an antioxidant stabilizer and method of manufacture |
CN103301513A (en) * | 2013-06-09 | 2013-09-18 | 诸辉 | Preparation method of intravascular stent with pharmaceutical enzyme coating |
US9751081B2 (en) | 2014-12-01 | 2017-09-05 | Clemson University | Self-regenerating antioxidant catalysts and methods of using the same |
CN104511084A (en) * | 2014-12-30 | 2015-04-15 | 深圳市信立泰生物医疗工程有限公司 | Balloon catheter |
CN105105892B (en) * | 2015-08-04 | 2017-03-29 | 北京康容源医疗器械有限公司 | A kind of medicament elution sacculus |
CN105105892A (en) * | 2015-08-04 | 2015-12-02 | 王显 | Medicine elution balloon |
CN111407930B (en) * | 2020-03-19 | 2021-01-08 | 中国科学院长春应用化学研究所 | Polymer bionic coating and preparation method thereof |
CN111407930A (en) * | 2020-03-19 | 2020-07-14 | 中国科学院长春应用化学研究所 | Polymer bionic coating and preparation method thereof |
CN111803718A (en) * | 2020-07-02 | 2020-10-23 | 西安交通大学医学院第二附属医院 | Anti-fibrosis drug sustained-release coating and preparation method thereof |
CN111803718B (en) * | 2020-07-02 | 2022-02-25 | 西安交通大学医学院第二附属医院 | Anti-fibrosis drug sustained-release coating and preparation method thereof |
CN112642045A (en) * | 2021-01-08 | 2021-04-13 | 北京先瑞达医疗科技有限公司 | Drug coating conveying device and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101264347A (en) | Drug coating applied to balloon surface of balloon catheter balloon for relieving vascular restenosis | |
EP1789107B1 (en) | Medical stent provided with inhibitors of atp synthesis | |
Mukerabigwi et al. | Therapeutic nanoreactors as in vivo nanoplatforms for cancer therapy | |
CN103736154B (en) | Medicinal coating balloon catheter | |
CN110201243B (en) | Composite drug coating balloon catheter and preparation method thereof | |
US6211247B1 (en) | Administration of resveratrol to prevent or treat restenosis following coronary intervention | |
EP1834637A1 (en) | Preventive/therapeutic composition for free radical disease | |
ES2676314T3 (en) | Coatings that release drugs for medical devices | |
JP5801874B2 (en) | Improved formulations for drug-coated medical devices | |
JPH07503010A (en) | Pharmaceutically active antioxidant-containing composition and method for preventing and treating restenosis after angioplasty using the composition | |
US20090324682A1 (en) | Medical stent provided with inhibitors of atp synthesis | |
Zhou et al. | Hypoxia-activated nanomedicines for effective cancer therapy | |
US8647680B2 (en) | Methods and compositions for treatment of lesioned sites of body vessels | |
US20140188036A1 (en) | Coating formulations for scoring or cutting balloon catheters | |
CN101264345A (en) | Degradable blood vessel stent drug coating capable of reducing late thrombosis incidence | |
CN1321090A (en) | Treatment of vascular restenosis | |
CN101264346A (en) | Degradable polymer blood vessel support medicine coating containing anticoagulation phosphorylcholine component | |
CN112704686B (en) | Preparation method of calcium phosphate-rapamycin composite medicine, preparation method of medicine coating balloon and medicine coating balloon | |
CN106267377A (en) | Drug coated balloon catheter | |
CN100431627C (en) | Blood ressel stent medicinal conting layer capable of relieving free radical harmful to cell after blood deficiency refilling | |
CN204219578U (en) | Containing the coating in blood vessel sacculus of Thalidomide layer | |
CN101496813B (en) | Applicance of combination in drug coating of preparing anti-hyperblastosis (vascular restenosis) support | |
EP3746006A1 (en) | Methods and devices for reducing vacular smooth muscle cell proliferation | |
Pawar et al. | Intravenous and regional paclitaxel formulations | |
CN101513540A (en) | Drug-eluting coronary artery stent and method for preparing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080917 |